Asset profile
Mebufotenin (5-MeO-DMT) · GH001
Small molecule
Evidence outlook · lead readout
NCT05800860 · Treatment-resistant Depression
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT05800860: The study randomly assigned 81 participants and used quadruple blinding with a placebo comparator. Its primary endpoint was the change in MADRS depression scores from baseline to Day 7. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 59 same-indication; 24 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mebufotenin (5-MeO-DMT) (GH001): this drug | Phase 2 | Small molecule | 5-HT2A receptor | ||
| CYB003 | Phase 3 | Small molecule | 5-HT2A receptor | ||
| Lysergide Tartrate (LSD) (DT120) | Phase 3 | Small molecule | 5-HT2A receptor | ||
| Psilocybin (COMP360) | Phase 3 | Small molecule | 5-HT2A receptor | ||
| BPL-003 (mebufotenin Benzoate) | Phase 2 | Small molecule | 5-HT2A receptor | ||
| Bretisilocin | Phase 2 | Small molecule | 5-HT2A receptor | ||
| VLS-01 | Phase 2 | Small molecule | 5-HT2A receptor | ||
| ELE-101 | Phase 1/2 | Small molecule | 5-HT2A receptor | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor | ||
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | ||
| Olanzapine / Fluoxetine (Symbyax) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); serotonin transporter (reuptake inhibitor) | ||
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (1)
March 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.